A Double-blind, Multi-Center, Prospective, Randomized Placebo-controlled Pilot Study Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects with Ankle Osteoarthritis. The goal of this pilot study and subsequent pivotal trial is to evaluate the safety and effectiveness of Axolotl Ambient intra-articular injection for ameliorating the pain and dysfunction associated with ankle OA.
This pilot study is a double-blind multi-center, prospective, randomized, placebo-controlled trial. Upon randomization, patients will receive 1 intraarticular injection of the investigational product or control fluid. Follow-up will be conducted at 4 weeks, 3 and 6 months, with 6 months serving as the primary endpoint. The primary outcomes will consist of patient reported outcomes of pain and functional assessment by the physician, specific to the foot and ankle. Subjects will be monitored for an additional 6 months to establish safety over a 1-year follow-up and evaluate the durability of benefit.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
12
Axolotl Ambient is an allogeneic amniotic intra-articular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.
"Drug/Placebo: 0.9% Normal Saline"
Injury Care Research
Boise, Idaho, United States
Orthopedic Specialists of Louisiana
Shreveport, Louisiana, United States
OrthoCarolina Foot and Ankle Institute
Charlotte, North Carolina, United States
Proportion of patients achieving Composite Clinical Success
Changes from baseline to each follow-up timepoint (4 weeks, 3 and 6 months) will be calculated for each outcome metric and statistical significance of changes will be assessed through repeated measures ANOVA or a mixed effects model to accommodate missing data points. Two options (based on either AOS or FAOS scores) for CCS will be defined as: * Improvement in AOS (Pain and Function, independently) or FAOS (Pain and ADL, independently) subdomain scores of at least 20% from baseline AND * No medical or surgical intervention beyond allowed rescue medication AND * Absence of treatment-related SAEs
Time frame: 4 Weeks
Proportion of patients achieving Composite Clinical Success
Changes from baseline to each follow-up timepoint (4 weeks, 3 and 6 months) will be calculated for each outcome metric and statistical significance of changes will be assessed through repeated measures ANOVA or a mixed effects model to accommodate missing data points. Two options (based on either AOS or FAOS scores) for CCS will be defined as: * Improvement in AOS (Pain and Function, independently) or FAOS (Pain and ADL, independently) subdomain scores of at least 20% from baseline AND * No medical or surgical intervention beyond allowed rescue medication AND * Absence of treatment-related SAEs
Time frame: 3 Months
Proportion of patients achieving Composite Clinical Success
Changes from baseline to each follow-up timepoint (4 weeks, 3 and 6 months) will be calculated for each outcome metric and statistical significance of changes will be assessed through repeated measures ANOVA or a mixed effects model to accommodate missing data points. Two options (based on either AOS or FAOS scores) for CCS will be defined as: * Improvement in AOS (Pain and Function, independently) or FAOS (Pain and ADL, independently) subdomain scores of at least 20% from baseline AND * No medical or surgical intervention beyond allowed rescue medication AND * Absence of treatment-related SAEs
Time frame: 6 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Incidence of Adverse Events
An Adverse Event (AE) is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in study subjects whether or not considered related to the investigational product. This definition includes events related to the investigational product or the comparator and events related to the procedures involved.
Time frame: Baseline (Day 0) to 12 Months
Symptoms, Quality of Life and Sports and Recreation subscales of the FAOS
The FAOS score was developed to reflect a foot and ankle version of the Knee Osteoarthritis Outcomes Score (KOOS). The FAOS score includes symptoms, quality of life and sports and recreation subscales.
Time frame: Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
Visual Analog Scale for average ankle pain and worst ankle pain
The Visual Analog Scale (VAS) is a measure of pain intensity. It is a continuous scale comprised of a horizontal visual analog scale anchored by two verbal descriptors (one for each symptom extreme).
Time frame: Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
EuroQOL-5 dimension-5 level quality of life scale
EQ-5D-5L is a self-completed health status questionnaire that assesses quality of life.
Time frame: Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
Pain Catastrophizing Scale
The pain catastrophizing scale (PCS) is a 13-item questionnaire that asks participants to grade each item on a 5-point scale.
Time frame: Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
Current Working Status
Percent of subject responses, for each of the following work status categories, by the treatment and control groups, at each timepoint. Current Working status, at each timepoint will be collected as: Not working, unrelated to ankle Not working, related to ankle Working with major limitations related to ankle Working without limitations related to ankle
Time frame: Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
Modified Kellgren and Lawrence Grade
The modified Kellgren and Lawrence Grade (K-L Grade) classifies osteoarthritis using five grades based on evaluation of x-ray of the affected joint.
Time frame: Baseline (Day 0), 6 Months